Human Chorionic Gonadotropin (HCG) Market Size, Share and Trends 2025 to 2034

Human Chorionic Gonadotropin (HCG) Market Size and Forecast 2025 to 2034

The global human chorionic gonadotropin market size was calculated at USD 2.15 billion in 2024 and is predicted to reach around USD 2.94 billion by 2034, expanding at a CAGR of 3.20% from 2025 to 2034. The human chorionic gonadotropin market is driven by the rising prevalence of infertility and increased demand for assisted reproductive technologies (ART) such as in-vitro fertilization (IVF).

Human Chorionic Gonadotropin (HCG) Mark Key Takeaways

• North America dominated the global market with the largest market share of 41% in 2024.
• Asia-Pacific is observed to be the fastest growing in the market during the forecast period.
• By product type, the native human chorionic gonadotropin segment contributed the highest market share in 2024.
• By product type, the recombinant human chorionic gonadotropin segment is significant growth in the smart lighting market during the forecast period.
• By therapeutic area, the female infertility treatment segment captured the biggest market share in 2024.
• By therapeutic area, the male hypogonadism segment is anticipated to grow at the fastest CAGR during the forecast period.
• By distribution channel, the hospital pharmacies segment generated the major market share in 2024.
• By distribution channel, the retail pharmacies segment shows significant growth during the forecast period.

How is AI Helping the Maternal Recognition Process?

AI is being used to speed up the development of new medications, including those based on hCG. The time and expense needed for clinical trials can be decreased using machine learning algorithms to evaluate large datasets and forecast which chemicals may have medicinal promise. Patient hCG level monitoring is becoming simpler due to AI-powered diagnostic technologies, like machine learning algorithms built into test equipment or applications. Healthcare professionals can receive real-time feedback from these systems, guaranteeing prompt treatments when needed. Large-scale health data analysis from multiple sources is made possible by AI, which offers important insights into the wider uses of hCG. Researchers can use AI to find novel applications for hCG, such as weight loss or cancer treatment.

U.S. Human Chorionic Gonadotropin (HCG) Market Size and Growth 2025 to 2034

The U.S. human chorionic gonadotropin market size was exhibited at USD 620 million in 2024 and is projected to be worth around USD 840 million by 2034, growing at a CAGR of 3.34% from 2025 to 2034.

North America dominated the human chorionic gonadotropin market in 2024.  In North America, public awareness programs about reproductive health and infertility have been increasingly popular. More individuals and couples are seeking medical assistance as a result of the growing acceptance of reproductive therapies, such as the usage of hCG. Government and commercial sector support has also been crucial, with many organizations providing grants, educational opportunities, and financing for fertility research.

North America continues to dominate the global human chorionic gonadotropin market, with the United States and Canada emerging as key contributors. This dominance is attributed to a well-established healthcare infrastructure, robust insurance systems, and high awareness of fertility treatment options. Several government-backed reproductive health initiatives, coupled with substantial research funding, have further supported innovations in the hCG drug segment.  

In the U.S., significant governmental support through organizations such as the Centers for Disease Control and Prevention (CDC) and the National Institute of Child Health and Human Development (NICHD) has helped drive public access to fertility clinics and hormone therapy programs. Moreover, the presence of leading pharmaceutical companies engaged in hormone therapy development and the availability of FDA-approved products contribute significantly to regional market leadership.

• According to WHO, 17.5% of the adult population, which is around 1 in 6 worldwide, experience infertility, showing the urgent demand to increase access to affordable, high-quality fertility care for those in need.

Asia-Pacific is observed to be the fastest growing in the human chorionic gonadotropin market during the forecast period. Advanced reproductive services and fertility clinics are seeing a rise in both governmental and private funding. Greater access to fertility management medicines like hCG is made possible by the growth of medical institutions in underprivileged and rural areas. Many places strongly emphasize family-building customs and children's cultural value, even in the face of economic expansion and urbanization. Treatments utilizing hCG are increasingly being used to help with conception as infertility concerns develop.

Asia Pacific is poised to host the fastest-growing market over the next few years. This rapid expansion is fuelled by several interlinked factors: a rising population, increased infertility rates due to lifestyle changes, and improving access to healthcare in emerging economies. Countries such as India, China, South Korea, and Thailand are witnessing growing investments in the reproductive health sector, particularly in urban areas where demand for ART services is surging.  

The reduction in treatment costs and the emergence of local pharmaceutical companies offering generic versions of hCG have made fertility treatments more affordable to the middle-income population. Supportive government schemes promoting maternal and reproductive healthcare, including public-private partnerships in fertility clinics, are also playing a vital role in expanding access to hCG therapies across the region.

Market Overview

Treatments using assisted reproductive technology (ART), including intrauterine insemination (IUI) and in vitro fertilization (IVF), often involve the use of hCG. In women receiving fertility treatments, it aids in ovulation initiation and pregnancy maintenance. The market for hCG has expanded as a result of rising rates of infertility and the number of couples pursuing assisted reproductive techniques. Strict regulatory control applies to the hCG market, especially in the areas of diagnostic testing and fertility treatments.

• In addition to ensuring product safety, the FDA and other health authorities control the marketing and approval of hCG-based medications and treatments, which also affects the entry of new competitors into the market.

Market key trend

The human chorionic gonadotropin market is currently experiencing a steady growth trajectory, driven by rising demand in fertility treatments, weight management therapies, and hormone-related medical applications. One of the primary market trends involves the growing utilization of in vitro assisted reproductive technologies (ART), especially in vitro fertilization (IVF), where it plays a crucial role in inducing ovulation.

Increasing awareness about infertility issues, delayed family planning, and a higher acceptance of advanced reproductive methods have led to a surge in human chorionic gonadotropin (HCG)-based medication use. In parallel, the market is witnessing an increasing preference for recombinant hCG over urine-derived formulations, due to its improved safety profile, purity, and efficacy. Additionally, there is a growing trend of based therapies being combined with other hormonal treatments in both men and women to enhance reproductive outcomes.

Human Chorionic Gonadotropin (HCG) Mark Growth Factors

• The need for hCG in fertility therapies like IVF is being driven by the rising rate of infertility, which is caused by delayed pregnancies, changes in lifestyle, and other medical issues. The market is growing due to increased global awareness and acceptance of ART techniques.
• Pregnancy detection and other diagnostic applications are now more effective and widely available because of advancements in diagnostic testing techniques, such as quick and extremely sensitive hCG assays. This, as well as expanded healthcare infrastructure in emerging economies, influences adoption rates.

Market Scope

Market Dynamics

Driver

Increasing prevalence of infertility among couples

Delays in marriage and childbearing are becoming more common in developed nations, frequently due to financial, educational, or professional factors. Delaying parenthood might cause infertility issues in later life, increasing the need for assisted reproductive technologies like IVF and hCG-induced ovulation induction. Governments in some areas are aggressively supporting fertility therapies and reproductive health. Tax breaks or subsidies for infertility treatments can lower couples' expenses and increase care access.

Restraint

Regulatory challenges

The safety profile of any hormone-based treatment, including hCG, is of special interest to regulatory bodies. Side effects from hCG treatment can range from minor ones like mood swings, bloating, and headaches to more serious ones like ovarian hyperstimulation syndrome (OHSS) in women or possible long-term repercussions. These worries increase scrutiny and stiffen the approval procedure. Manufacturers must show that the advantages of hCG products outweigh the hazards of being licensed for new purposes, like weight loss. In certain situations, this can be difficult, particularly if there are concerns about the safety of off-label use.

Opportunity

Innovations in medical technologies and improvements in fertility treatment procedures

Fertility preservation techniques like egg freezing are growing in popularity as societal and cultural changes result in later-age pregnancies. The use of hCG in egg retrieval may become more common due to advancements in cryopreservation and egg thawing methods, which would raise the need for hCG products. A wider range of people can now receive fertility treatments because of the growth of telemedicine and remote consultations.

• This is particularly important in areas where access to fertility clinics is restricted. The demand for drugs like hCG, which are essential to many reproductive procedures, may increase as more people look for fertility treatments online.

Product Type Insights

The native human chorionic gonadotropin segment dominated the human chorionic gonadotropin market in 2023. The term "native hCG" describes the naturally occurring type of human chorionic gonadotropin, which is mostly obtained from pregnant women's urine. It is beneficial for therapeutic applications since it maintains its biological activity and natural structure. Recombinant hCG, created artificially through genetic engineering, is different from native hCG. The need for efficient treatments like native hCG has increased due to rising infertility rates globally, which are caused by factors like delayed pregnancies, lifestyle changes, and hormonal imbalances.

This pattern is especially noticeable in nations where fertility support is actively encouraged or where the population is declining. The recombinant human chorionic gonadotropin segment is observed to be the fastest growing in the human chorionic gonadotropin market during the forecast period.

In vitro fertilization (IVF) and intrauterine insemination (IUI) are two common ART treatments that use recombinant hCG to induce ovulation and improve pregnancy success rates. The market for hCG is being driven by nations, including the US, India, China, and Europe, that are adopting ART services at an increasing rate. Genetic engineering advancements have increased market adoption by enabling cost-effective production without sacrificing product quality.

Therapeutic Area Insights

The female infertility treatment segment dominated the human chorionic gonadotropin market in 2023. hCG therapy is a crucial medication in infertility treatment regimens since it helps women with ovulatory disorders. Recombinant hCG formulations have improved patient outcomes and therapy efficacy. Compared to urine-derived hCG, these formulations are more stable, dependable, and favored due to their lower immunogenicity. Medical solutions employing hCG are now more widely accepted as a result of awareness efforts and education about infertility treatments.

The male hypogonadism segment is observed to be the fastest growing in the human chorionic gonadotropin market during the forecast period. Insufficient synthesis of testosterone, a hormone necessary for male growth and reproductive processes, is a defining feature of male hypogonadism. This insufficiency may result from problems with the hypothalamic-pituitary axis (secondary hypogonadism) or testicular failure (primary hypogonadism). Younger males with secondary hypogonadism are using hCG at increased rates because of growing awareness of fertility preservation.

• The use of hCG is further supported by clinical research that demonstrates how it enhances testosterone levels, sexual function, and quality of life in hypogonadal males.

Distribution Channel Insights

The hospital pharmacies segment dominated the human chorionic gonadotropin market in 2023.  Human chorionic gonadotropin is frequently used to treat male hypogonadism and female infertility. Hospitals are often the primary focus of care for patients with these complex diseases when they get hCG-based treatments and undergo comprehensive assessments. When given via injection, human chorionic gonadotropin necessitates exact quantities. Under expert supervision, hospital pharmacies can guarantee that patients receive the appropriate dosages.

The retail pharmacies segment shows a significant growth in the human chorionic gonadotropin market during the forecast period. Infertility in women, hypogonadism in males, and other hormonal deficiencies are commonly treated using human chorionic gonadotropin. These therapies are conveniently distributed via retail pharmacies, making it simpler to obtain prescription drugs. Retail pharmacies frequently provide longer hours than hospitals or specialty clinics, making it easy for patients to buy prescription drugs. Several retail chains have begun to improve adherence to hCG treatment regimens by providing digital prescriptions, appointment scheduling, and automated reminders for medicine refills.

Human Chorionic Gonadotropin (HCG) Market Companies

• Aspen API
• Livzon Pharmaceuticals
• Lupin
• Merck & Co., Inc.
• Scripps Laboratories
• Shanghai Techwell Biopharmaceutical Co. Ltd.
• Sun Pharmaceuticals Ltd.
• Zydus Lifesciences Ltd.
• Merck Serono
• Ningbo Renjian Pharmaceutical Group Co. Ltd.
• Sanzyme
• Ferring Pharmaceuticals
• Fresenius Kabi

Recent updates on Human Chorionic Gonadotropin

Innovations in hCG therapies enhance reproductive health 

On 10 March 2025, significant progress was made in the market for human chorionic gonadotropin especially in the creation of recombinant hCG formulations. By lowering immunogenicity and increasing bioavailability these developments hope to provide patients undergoing fertility treatments with safer and more efficient alternatives. Recombinant technology adoption is part of a larger biopharmaceuticals trend that emphasizes accuracy and patient centered care.

Manufacturers are also concentrating on using more environmentally friendly synthesis techniques to lower production costs. Oral and transdermal hCG delivery techniques are also becoming more popular as the need for minimally invasive treatments increases.

Expanding applications of hCD in therapeutic areas 

• In April 2025, beyond reproductive health research was conducted on hCGs potential therapeutic uses. New research has investigated how it might be used to treat autoimmune diseases and other ailments like cachexia. These studies point to a bright future for hCG as a versatile medicinal substance that may increase both its market demand and clinical utility. Additionally, its anabolic and anti-inflammatory qualities are being researched for possible uses in chronic fatigue syndrome and sports medicine. Both established pharmaceutical companies and biotech entrepreneurs are showing interest in this diversification.

Recent Developments

• In January 2025, a leading biopharmaceutical company announced the development of a novel oral hCG formulation, aiming to enhance patient compliance by offering a non-invasive alternative to traditional injections.
• In February 2025, a collaborative research initiative between academic institutions and industry partners commenced a clinical trial to evaluate the efficacy of hCG in managing autoimmune conditions, marking a potential expansion of its therapeutic indications. 
• In March 2025, advancements in nanotechnology facilitated the creation of hCG-loaded nanoparticles designed for targeted drug delivery, potentially improving treatment outcomes and minimizing side effects.
• In April 2025, regulatory authorities approved a new biosimilar hCG product, increasing market competition and potentially reducing treatment costs for patients requiring hCG therapy.
• In May 2024, Turkiye requested India to provide Gonadotropin drugs used in obstetrics and gynecology due to the high need for in-vitro fertilization in Turkiye.
• In June 2022, Inception Fertility (Inception) enlivened its ecosystem, including the launch of HavenCryo, a long-term reproductive tissue and cryopreservation storage solution that provides a unique experience for fertility providers and patients.

Segments Covered in the Report 

By Product Type

• Native Human Chorionic Gonadotropin
• Recombinant Human Chorionic Gonadotropin

By Therapeutic Area

• Female Infertility Treatment
• Male Hypogonadism
• Oligospermic Treatment
• Cryptorchidism Treatment
• Chronic Pain
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Geography

• North America
• Asia Pacific
• Europe
• Latin America
• Middle East and Africa